Sichuan Kelun-biotech Biopharmaceutical Cancer Drug Gets Regulatory Nod; Shares Up 4%

MT Newswires Live06-18

Sichuan Kelun-biotech Biopharmaceutical (HKG:6990) said the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) approved the investigational new drug application for the innovative drug SKB518, according to a Monday filing on the Hong Kong bourse.

SKB518 for injection is used to treat solid tumors. The pharmaceutical plans to undertake clinical trials for the medication.

The companyâs shares were up by over 4% in recent trading.

Price (HKD): $179.50, Change: $+7.30, Percent Change: +4.24%

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2444710863?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-06-18 16:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2444710863","market":"sh","top_or_hot":-1,"title":"Sichuan Kelun-biotech Biopharmaceutical Cancer Drug Gets Regulatory Nod; Shares Up 4%","media":"MT Newswires Live","content":"<html><body><p> Sichuan Kelun-biotech Biopharmaceutical (HKG:6990) said the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) approved the investigational new drug application for the innovative drug SKB518, according to a Monday filing on the Hong Kong bourse. </p><p>SKB518 for injection is used to treat solid tumors. The pharmaceutical plans to undertake clinical trials for the medication. </p><p>The companyâs shares were up by over 4% in recent trading.  </p><p>Price (HKD): $179.50, Change: $+7.30, Percent Change: +4.24%</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sichuan Kelun-biotech Biopharmaceutical Cancer Drug Gets Regulatory Nod; Shares Up 4%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSichuan Kelun-biotech Biopharmaceutical Cancer Drug Gets Regulatory Nod; Shares Up 4%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-06-18 16:04 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sichuan Kelun-biotech Biopharmaceutical (HKG:6990) said the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) approved the investigational new drug ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4017","symbol_name":"黄金","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2444710863","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2444710863","pubTimestamp":1718697873,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Sichuan Kelun-biotech Biopharmaceutical  said the Center for Drug Evaluation  of China's National Medical Products Administration  approved the investigational new drug application for the innovative drug SKB518, according to a Monday filing on the Hong Kong bourse. SKB518 for injection is used to treat solid tumors. The pharmaceutical plans to undertake clinical trials for the medication. The companys shares were up by over 4% in recent trading.  Price : $179.50, Change: $+7.30, Percent Change: +4.24%","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4017":"黄金","BK4585":"ETF&股票定投概念","BK1161":"生物科技","06990":"科伦博泰生物-B","CDE":"科尔黛伦矿业","BK4588":"碎股","BK4526":"热门中概股","BK4023":"应用软件","HKD":"尚乘数科"},"translate_title":"四川科伦生物制药抗癌药物获得监管部门批准；股价上涨4%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CDE":1,"HKD":1,"06990":0.9},"content_text":"Sichuan Kelun-biotech Biopharmaceutical (HKG:6990) said the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) approved the investigational new drug application for the innovative drug SKB518, according to a Monday filing on the Hong Kong bourse. SKB518 for injection is used to treat solid tumors. The pharmaceutical plans to undertake clinical trials for the medication. The companyâs shares were up by over 4% in recent trading.  Price (HKD): $179.50, Change: $+7.30, Percent Change: +4.24%","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.28.1","shortVersion":"4.28.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2444710863"}